Services
We provide three services: OncoAct, OncoAnalyserDx and Hartwig Sequencing Services.
OncoAct
Cancer is caused by DNA mutations. To find these mutations, we developed OncoAct. OncoAct is a complete DNA test that can provide physicians with additional information about clinically relevant characteristics of a tumor (biomarkers) that may also be predictive of the response to treatment.
Changes in the genetic profile (mutations) sometimes provide clues to a potential treatment that can directly target these mutations. This is known as targeted therapy.
In addition, the OncoAct report contains possible leads for trials or experimental drugs.
We have an agreement with most hospitals to carry out OncoAct for them. Would you like to know which hospitals these are and who the contact person is within your hospital? Please email info@oncoact.nl.
OncoAnalyserDx RUO
For Australia and Research Use Only
Hartwig Medical Foundation has developed software tools to analyse Next Generation Sequencing (NGS) data to detect genomic events in tumors. After extensive validations and landmark publications, these open-source tools called WiGiTS have proven to deliver comprehensive molecular analyses. Collaborators at the University of Melbourne, assembled WiGiTS into a single pipeline called oncoanalyser and made it freely available to the community via nf-core.
Oncoanalyser is now being incorporated into a Software as a Service (SaaS) cloud-based platform called OncoAnalyserDx. OncoAnalyserDx is in development with early access testing partners and is currently Research Use Only.
Sequencing Services
We sequence and analyze DNA for research purposes.
A complete genetic analysis should be part of the standard diagnostics for every patient with cancer who is eligible for treatment. WGS contributes to better, coordinated treatment advice. In this way, we reduce over- and under-treatment, while making healthcare more cost-effective and keeping it affordable.